TRDA Stock Summary and Trading Ideas (Entrada Therapeutics | NASDAQ:TRDA)

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

What symbol and exchange does Entrada Therapeutics shares trade?

Entrada Therapeutics trades on the NASDAQ stock market under the symbol TRDA.

What is Entrada Therapeutics stock price doing today?

As of December 15, 2025, TRDA stock price declined to $11.03 with 167,264 million shares trading.

What is Entrada Therapeutics's Beta?

TRDA has a beta of 1.14, meaning it tends to be more sensitive to market movements. TRDA has a correlation of 0.10 to the broad based SPY ETF.

How much is Entrada Therapeutics worth?

TRDA has a market cap of $421.56 million. This is considered a Small Cap stock.

How much money does Entrada Therapeutics make?

Last quarter Entrada Therapeutics reported $2 million in Revenue and -$1.06 earnings per share. This fell short of revenue expectation by $-6 million and missed earnings estimates by -$.07.

What is the highest and lowest price Entrada Therapeutics traded in the last 3 year period?

In the last 3 years, TRDA traded as high as $21.79 and as low as $4.93.

What are the top ETFs holding Entrada Therapeutics?

The top ETF exchange traded funds that TRDA belongs to (by Net Assets): VTI, IWM, IWN, VXF, IBB.

Is Entrada Therapeutics (TRDA) a good investment?

TRDA has underperformed the market in the last year with a return of -37.5%, while SPY returned +13.9%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in TRDA shares. However, TRDA has outperformed the market in the last 3 month and 2 week periods, returning +118.0% and +11.3%, while SPY returned +3.3% and +0.1%, respectively. This indicates TRDA has been having a stronger performance recently.

What are the support and resistance levels for Entrada Therapeutics (TRDA)?

TRDA support price is $10.56 and resistance is $11.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TRDA shares will trade within this expected range on the day.